| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 72.8 | ¤866,871 | US |
| JNJ | Johnson & Johnson | 62.9 | ¤572,592 | US |
| MRK | Merck & Co., Inc. | 63.0 | ¤282,347 | US |
| AMGN | Amgen Inc. | 65.4 | ¤188,631 | US |
| ABT | Abbott Laboratories | 45.5 | ¤186,262 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| PODD | Insulet Corporation | 63.5 | ¤16,095 | US |
| ZBH | Zimmer Biomet Holdings, Inc. | 50.6 | ¤17,577 | US |
| DGX | Quest Diagnostics Incorporated | 54.3 | ¤21,332 | US |
| STE | STERIS plc | 58.8 | ¤21,372 | IE |
| LH | Labcorp Holdings Inc. | 50.0 | ¤21,761 | US |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 65.4 | 31 | US |
| LLY | Eli Lilly and Company | 72.8 | 26 | US |
| PFE | Pfizer Inc. | 51.0 | 24 | US |
| DGX | Quest Diagnostics Incorporated | 54.3 | 22 | US |
| ZTS | Zoetis, Inc. Class A | 62.8 | 22 | US |
| BMY | Bristol-Myers Squibb Company | 62.3 | 21 | US |
| JNJ | Johnson & Johnson | 62.9 | 21 | US |
| TMO | Thermo Fisher Scientific Inc. | 48.0 | 21 | US |
| RMD | ResMed Inc. | 72.4 | 19 | US |
| GILD | Gilead Sciences, Inc. | 71.0 | 18 | US |
| Average Market Cap | ¤0 |
| Median Market Cap | ¤0 |
| Avg. 3 Mo. Dollar Vol. | ¤0 |
| Avg. 3 Mo. Trading Vol. | 0 |
| Last Rebalance Date | N/A |
| Companies Replaced | |
| Biggest Increase | |
| Biggest Decrease |
| Trailing P/E Ratio (12 Mo.) | 0.0 |
| Forward P/E Ratio (12 Mo.) | 0.0 |
| Price/Book Ratio | 0.0 |
| Avg. Revenue Chg. - 3 Yr | 0.0% |
| Avg. Op. Income Chg. - 3 Yr. | 0.0% |
| Avg. EPS Growth - 3 Yr. | 0.0% |
| Avg. EPS Growth - 1 Yr. | 0.0% |
| Avg. Operating Margin | 0.0% |
| Avg. LT Debt to Total Capital | 0.0% |
| Avg. Return on Equity | 0.0% |
| Dividend Yield | 0% |
| 0.0 |
| United States Of America | 90.0% |
| Ireland | 6.67% |
| Switzerland | 3.33% |
